Resources

Yseop was recently featured in mind Health, where Pierre-Louis Durel, VP Strategy & Operations, shared how AI is transforming regulatory writing—and why it is becoming a critical lever for accelerating access to new therapies.

Generative AI can accelerate regulatory content—but speed is not the challenge. Trust is. As life sciences organizations move beyond pilots, a new standard is emerging: regulatory-grade AI, powered by neuro-symbolic architectures designed for accuracy, traceability, and control.

The AI transformation underway in life sciences regulatory affairs is understated, yet tangible and grounded. It is a quiet revolution: instead of pursuing speculative intelligence, organizations are applying AI to automate predictable, rules-driven regulatory work.

Yseop wins the 2026 BIG Innovation Award, recognized for transforming regulatory writing with GenAI

Why do AI pilots fail to scale in life sciences regulatory teams? Based on our experience supporting AI adoption in regulatory environments worldwide, this article explains what successful teams do differently.

The promise of AI in pharma has been circulating for years. In 2025, the industry stopped talking about potential and started designing around it.

Yseop recognized by TIME for transforming how life sciences teams create regulatory documents with AI automation.

A Whitepaper That Looks at How GenAI-Powered Automation Is Helping Teams Prepare for the Future of Regulatory Submissions

Claret Capital Partners has invested €10M in Yseop to support global expansion and accelerate development of its Generative AI platform. Yseop Copilot helps leading pharma companies like Eli Lilly and Novartis create compliant regulatory documentation faster and with greater consistency.